The Japan Society of Clinical Oncology Clinical Practice Guidelines 2022 for gastrointestinal stromal tumor (GIST) have been published in accordance with the Minds Manual for Guideline Development 2014 and 2017. A specialized team independent of the working group for the revision performed a systematic review. Since GIST is a rare type of tumor, clinical evidence is not sufficient to answer several clinical and background questions. Thus, in these guidelines, we considered that consensus among the experts who manage GIST, the balance between benefits and harms, patients’ wishes, medical economic perspective, etc. are important considerations in addition to the evidence. Although guidelines for the treatment of GIST have also been published by the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO), there are some differences between the treatments proposed in those guidelines and the treatments in the present guidelines because of the differences in health insurance systems among countries.

日本临床肿瘤学会2022年胃肠道间质瘤（GIST）临床实践指南已根据2014年和2017年指南制定Minds手册发布。独立于修订工作组的专业团队进行了系统审查。由于胃肠道间质瘤是一种罕见的肿瘤，临床证据不足以回答一些临床和背景问题。因此，在这些指南中，我们认为除了证据之外，治疗GIST的专家之间的共识、利弊之间的平衡、患者的意愿、医疗经济观点等也是重要的考虑因素。尽管美国国家综合癌症网络（NCCN）和欧洲肿瘤内科学会（ESMO）也发布了 GIST 治疗指南，但这些指南中提出的治疗方法与现行指南中的治疗方法之间存在一些差异，因为各国医疗保险制度的差异。